title: Iron deficiency anemia and levels of oxidative stress induced by treatment modality.
abstract: BACKGROUND
  The effects of iron deficiency anemia (IDA) and its treatment on plasma total antioxidant capacity (TAOC) were investigated.
  
  
  METHODS
  Sixty patients with IDA and 20 healthy controls were divided into four subgroups: an oral (per os: PO) group (n = 20); an intramuscular (IM) group (n = 20); an intravenous (IV) group (n = 20); and the control group (n = 20). Blood samples were obtained from all patients before treatment, and at 24 h, 7 days, 6 and 13 weeks after initiation of IDA therapy.
  
  
  RESULTS
  TAOC in the IDA group was low when compared with the control group (P < 0.001). Although TAOC at 24 h in the PO group was not different from the control group, the TAOC in the IM and IV groups was relatively lower (P < 0.001). The TAOC in the PO group at 7 days, and at 6 and 13 weeks was closest to the control group level. The mean TAOC in the IV group at 13 weeks was clearly lower relative to the PO and IM groups.
  
  
  CONCLUSIONS
  Oxidative stress was minimally induced with oral therapy, while IM and IV therapies induced higher levels of oxidative stress, in increasing order of intensity.
authors: Division of Hematology, Firat University Faculty of Medicine, Elazig, Turkey. aksaadet@yahoo.com
authors: Saadet
authors: S
authors: Akarsu
authors: Hatice
authors: H
authors: Demir
authors: Sahabettin
authors: S
authors: Selek
authors: Ferdane
authors: F
authors: Oguzoncul
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D018798:Anemia, Iron-Deficiency / Q000097:blood* / Q000188:drug therapy*; D000975:Antioxidants / Q000378:metabolism*; D002648:Child; D002675:Child, Preschool; D003906:Developing Countries; D004305:Dose-Response Relationship, Drug; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage*; D000077605:Ferric Oxide, Saccharated; D005296:Ferrous Compounds / Q000008:administration & dosage*; D005937:Glucaric Acid; D005998:Glycine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006452:Hemoglobinometry; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D007273:Injections, Intramuscular; D008297:Male; D018384:Oxidative Stress / Q000502:physiology*; D013395:Sucrose / Q000008:administration & dosage*; D014421:Turkey
chemical_list: D000975:Antioxidants; D005290:Ferric Compounds; D005296:Ferrous Compounds; D013395:Sucrose; D000077605:Ferric Oxide, Saccharated; C030676:ferroglycine sulfate; D005937:Glucaric Acid; D005998:Glycine; C013276:teferrol